US2005266504A1PendingUtilityA1

Methods for diagnosing and treating Alzheimers disease and Parkinson's disease

33
Individually held — no corporate assignee on recordPriority: Jul 20, 2001Filed: Aug 10, 2005Published: Dec 1, 2005
Est. expiryJul 20, 2021(expired)· nominal 20-yr term from priority
Inventors:Paul F. GoodD. Stave Kohtz
G01N 33/6896C07K 16/44C07K 2317/77Y10S530/839G01N 2800/2821G01N 2800/2835
33
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a method for diagnosing Alzheimer's disease and Parkinson's disease in a subject by analyzing the expression of Semaphorin 3 and downstream effectors. It also provides a method for identifying a substance useful in the prevention or treatment of Alzheimer's disease and Parkinson's disease, and a method of using such substance in the treatment of Alzheimer's disease and Parkinson's disease.

Claims

exact text as granted — not AI-modified
1 . (canceled)  
     
     
         2 . (canceled)  
     
     
         3 . (canceled)  
     
     
         4 . (canceled)  
     
     
         5 . (canceled)  
     
     
         6 . (canceled)  
     
     
         7 . (canceled)  
     
     
         8 . (canceled)  
     
     
         9 . (canceled)  
     
     
         10 . (canceled)  
     
     
         11 . (canceled)  
     
     
         12 . (canceled)  
     
     
         13 . (canceled)  
     
     
         14 . (canceled)  
     
     
         15 . (canceled)  
     
     
         16 . (canceled)  
     
     
         17 . (canceled)  
     
     
         18 . (canceled)  
     
     
         19 . A method for identifying a substance useful in the prevention or treatment of Alzheimer's disease or Parkinson's disease, which method comprises determining the effect of the substance on an activity of a class 3 Semaphorin, wherein an inhibitory effect is indicative of a substance useful in the prevention or treatment of Alzheimer's disease or Parkinson's disease.  
     
     
         20 . The method according to  claim 19 , wherein the member of the class 3 Semaphorin is Semaphorin 3A.  
     
     
         21 . The method according to  claim 20 , wherein the Semaphorin 3A is human Semaphorin 3A.  
     
     
         22 . The method according to  claim 19 , wherein determining the effect of the substance on the activity of Semaphorin 3 comprises: 
 (a) contacting a test cell with the substance and Semaphorin 3 under conditions wherein addition of Semaphorin 3A alone induces apoptosis of the cell; and    (b) observing the effect of addition of the substance and Semaphorin 3 on the cell, in comparison with the effect of addition of Semaphorin 3 alone to a control cell, wherein inhibition of apoptosis of the test cell compared to the control cell is indicative of a substance useful in the prevention or treatment of Alzheimer' disease or Parkinson's disease.    
     
     
         23 . The method according to  claim 22 , wherein the cell used in step (a) is a neuronal cell.  
     
     
         24 . The method according to  claim 23 , wherein the neuronal cell is located within the hippocampus, substantia nigra, thalamus, or a neoplasm.  
     
     
         25 . A method for identifying a substance useful in the prevention or treatment of Alzheimer's disease, which method comprises determining the effect of the substance on an activity of a class 3 Semaphorin, wherein an inhibitory effect is indicative of a substance useful in the prevention or treatment of Alzheimer's disease or Parkinson's disease, and wherein determining the effect of the substance on the activity of the class 3 Semaphorin comprises: 
 (a) contacting a test neuronal cell with the substance and the class 3 Semaphorin under conditions wherein addition of the class 3 Semaphorin alone induces withdrawal, retraction or collapse of the nerve growth cone; and    (b) observing the effect of the addition of the substance and the class 3 Semaphorin on the test cell, in comparison with the effect of addition of the class 3 Semaphorin alone or to a control cell, wherein inhibition of withdrawal, retraction, or collapse of the nerve growth cone in the test cell compared to the control cell is indicative of a substance useful in the prevention or treatment of Alzheimer's disease.    
     
     
         26 . The method according to  claim 19 , wherein determining the effect of the substance on the activity of a class 3 Semaphorin comprises determining the effect of the substance on the binding or activation of a class 3 Semaphorin receptor by the class 3 Semaphorin, wherein an antagonist effect indicates that the substance is useful in the prevention or treatment of Alzheimer's disease or Parkinson's disease.  
     
     
         27 . The method according to  claim 19 , wherein the inhibitory effect of the substance is determined in vivo, by administering the substance to an animal that shows a level of the class 3 Semaphorin protein superior to that in a control animal.  
     
     
         28 . The method according to  claim 19 , wherein the animal is a transgenic animal that overexpresses the class 3 Semaphorin.  
     
     
         29 . (canceled)  
     
     
         30 . (canceled)  
     
     
         31 . (canceled)  
     
     
         32 . (canceled)  
     
     
         33 . (canceled)  
     
     
         34 . (canceled)  
     
     
         35 . The method according to  claim 25 , wherein the member of the class 3 Semaphorin is Semaphorin 3A.  
     
     
         36 . The method according to  claim 35 , wherein the Semaphorin 3A is human Semaphorin 3A.  
     
     
         37 . The method according to  claim 25  wherein determining the effect of the substance on the activity of a class 3 Semaphorin comprises determining the effect of the substance on the binding or activation of a class 3 Semaphorin receptor by the class 3 Semaphorin, wherein an antagonist effect indicates that the substance is useful in the prevention or treatment of Alzheimer's disease or Parkinson's disease.  
     
     
         38 . The method according to  claim 25 , wherein the inhibitory effect of the substance is determined in vivo, by administering the substance to an animal that shows a level of the class 3 Semaphorin protein superior to that in a control animal.  
     
     
         39 . The method according to  claim 25 , wherein the animal is a transgenic animal that overexpresses the class 3 Semaphorin.  
     
     
         40 . A method for identifying a substance useful in the prevention or treatment of Alzheimer's disease or Parkinson's disease, which method comprises determining the effect of the substance on an activity of a member of a class 3 Semaphorin signaling complex, wherein an inhibitory effect is indicative of a substance useful in the prevention or treatment of Alzheimer's disease or Parkinson's disease.  
     
     
         41 . The method according to  claim 40 , wherein the member of the class 3 Semaphorin signaling complex is Semaphorin 3A.  
     
     
         42 . The method according to  claim 25 , wherein the member of the class 3 Semaphorin signaling complex is selected from the group consisting of microtubule assembly (MAP 1 B), tau, collapsin response mediator protein 2 (CRMP 2), Neuropilin 1, Neuropilin 2, Plexin A1, and Plexin A2.  
     
     
         43 . The method of  claim 42 , wherein activity is regulated by phosphorylation.  
     
     
         44 . The method of  claim 42 , wherein the activity is kinase activity.  
     
     
         45 . The method of  claim 42 , wherein the activity is oligomerization.

Join the waitlist — get patent alerts

Track US2005266504A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.